Summary

The 7 major agoraphobia markets reached a value of US$ 461.5 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 814.4 Million by 2034, exhibiting a growth rate (CAGR) of 5.3% during 2024-2034.

The agoraphobia market has been comprehensively analyzed in IMARC's new report titled "Agoraphobia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Agoraphobia refers to an anxiety disorder characterized by a persistent and intense fear of situations or places where escape might be difficult, embarrassing, or impossible. The symptoms of agoraphobia can vary in severity and can be both physical and emotional. Some of the common signs are intense anxiety or panic attacks, avoiding situations or places that trigger anxiety, feeling a sense of helplessness or detachment from reality, feeling trapped or confined in certain conditions, etc. Various physical indications, such as rapid heartbeat, sweating, trembling, excessive worry or fear about being alone or outside of the home, etc., can also be observed. Additionally, individuals with agoraphobia may experience social isolation, depression, and difficulty with daily activities, including work, school, or errands. The diagnosis usually involves a review of the patient's medical history, a physical examination, and a psychiatric evaluation. The mental health professional will ask the patient about their symptoms, such as the frequency, duration, and intensity of their anxiety or panic attacks. They may also use various diagnostic tools, including questionnaires or interviews, to help make an accurate diagnosis.

The increasing prevalence of anxiety and panic disorders is primarily driving the agoraphobia market. In addition to this, the rising utilization of medications, such as selective serotonin reuptake inhibitors (SSRIs), benzodiazepines, beta-blockers, etc., to reduce anxiety and panic symptoms is creating a positive outlook for the market. Moreover, the growing emphasis on timely intervention, including screening and early detection programs, to prevent long-term complications for individuals with anxiety disorders is also propelling the market. Apart from this, the widespread adoption of digital therapeutics, such as smartphone apps and web-based programs that provide access to cognitive behavioral therapy and relaxation techniques, in conjunction with traditional therapy or as a standalone treatment, is further acting as another significant growth-inducing factor. Additionally, the emerging popularity of virtual reality exposure therapy, which involves using virtual reality technology to simulate and expose patients to feared situations in a safe and controlled environment, for managing agoraphobia is also augmenting the market. Furthermore, the escalating demand for personalized and patient-centered care for mental health disorders, including agoraphobia, is driving the development of new treatment options and the customization of existing treatments. This, in turn, is expected to drive the agoraphobia market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the agoraphobia market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for agoraphobia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the agoraphobia market in any manner.

Time Period of the Study

Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the agoraphobia market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the agoraphobia market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current agoraphobia marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:
Market Insights

How has the agoraphobia market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the agoraphobia market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the agoraphobia market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (​2018-2034​) of agoraphobia across the seven major markets?
What is the number of prevalent cases (​2018-2034​) of agoraphobia by age across the seven major markets?
What is the number of prevalent cases (​2018-2034​) of agoraphobia by gender across the seven major markets?
How many patients are diagnosed (​2018-2034​) with agoraphobia across the seven major markets?
What is the size of the agoraphobia patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of agoraphobia?
What will be the growth rate of patients across the seven major markets?

Agoraphobia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for agoraphobia drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the agoraphobia market?
What are the key regulatory events related to the agoraphobia market?
What is the structure of clinical trial landscape by status related to the agoraphobia market?
What is the structure of clinical trial landscape by phase related to the agoraphobia market?
What is the structure of clinical trial landscape by route of administration related to the agoraphobia market?

ページTOPに戻る

Table of Contents

1 Preface

2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Agoraphobia - Introduction
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence

5 Agoraphobia - Disease Overview
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment

6 Patient Journey

7 Agoraphobia - Epidemiology and Patient Population
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (​2018-2034​)
7.2.4 Epidemiology by Gender (​2018-2034​)
7.2.5 Diagnosed Cases (​2018-2034​)
7.2.6 Patient Pool/Treated Cases (​2018-2034​)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (​2018-2034​)
7.3.4 Epidemiology by Gender (​2018-2034​)
7.3.5 Diagnosed Cases (​2018-2034​)
7.3.6 Patient Pool/Treated Cases (​2018-2034​)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (​2018-2034​)
7.4.4 Epidemiology by Gender (​2018-2034​)
7.4.5 Diagnosed Cases (​2018-2034​)
7.4.6 Patient Pool/Treated Cases (​2018-2034​)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (​2018-2034​)
7.5.4 Epidemiology by Gender (​2018-2034​)
7.5.5 Diagnosed Cases (​2018-2034​)
7.5.6 Patient Pool/Treated Cases (​2018-2034​)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (​2018-2034​)
7.6.4 Epidemiology by Gender (​2018-2034​)
7.6.5 Diagnosed Cases (​2018-2034​)
7.6.6 Patient Pool/Treated Cases (​2018-2034​)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (​2018-2034​)
7.7.4 Epidemiology by Gender (​2018-2034​)
7.7.5 Diagnosed Cases (​2018-2034​)
7.7.6 Patient Pool/Treated Cases (​2018-2034​)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (​2018-2034​)
7.8.4 Epidemiology by Gender (​2018-2034​)
7.8.5 Diagnosed Cases (​2018-2034​)
7.8.6 Patient Pool/Treated Cases (​2018-2034​)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (​2018-2034​)
7.9.4 Epidemiology by Gender (​2018-2034​)
7.9.5 Diagnosed Cases (​2018-2034​)
7.9.6 Patient Pool/Treated Cases (​2018-2034​)

8 Agoraphobia - Treatment Algorithm, Guidelines, and Medical Practices
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm

9 Agoraphobia - Unmet Needs

10 Agoraphobia - Key Endpoints of Treatment

11 Agoraphobia - Marketed Products
11.1 List of Agoraphobia Marketed Drugs Across the Top 7 Markets
11.1.1 Prozac (Fluoxetine) - Eli Lilly
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Paxil (Paroxetine) - Novo Nordisk
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

12 Agoraphobia - Pipeline Drugs
12.1 List of Agoraphobia Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status

Kindly note that the complete list of pipeline drugs has been provided in the report.

13. Agoraphobia - Attribute Analysis of Key Marketed and Pipeline Drugs

14. Agoraphobia – Clinical Trial Landscape
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events

15 Agoraphobia - Market Scenario
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Agoraphobia - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Agoraphobia - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Agoraphobia - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Agoraphobia - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Agoraphobia - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Agoraphobia - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Agoraphobia - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Agoraphobia - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Agoraphobia - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Agoraphobia - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Agoraphobia - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Agoraphobia - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Agoraphobia - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Agoraphobia - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Agoraphobia - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Agoraphobia - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Agoraphobia - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Agoraphobia - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Agoraphobia - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Agoraphobia - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Agoraphobia - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Agoraphobia - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Agoraphobia - Access and Reimbursement Overview

16 Agoraphobia - Recent Events and Inputs From Key Opinion Leaders

17 Agoraphobia Market - SWOT Analysis
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats

18 Agoraphobia Market – Strategic Recommendations

19 Appendix